People with higher blood levels of certain manufactured compounds that persist in the environment are more likely to be ...

A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...

Fear of relapse and worsening disease is common for MS patients, leading to poorer mental health, per a study calling for ...

The CEMIP enzyme inhibits the growth of oligodendrocytes and may serve as a therapeutic target to boost myelin repair in MS, ...

MS relapses are more common in spring and summer, coinciding with warmer, drier weather and atmospheric changes, a study ...

A clinical trial testing whether music therapy can make botulinum toxin injections for spasticity more comfortable is ...

Taking lipoic acid failed to ease progressive MS symptoms in a clinical trial, but the antioxidant showed signs of slowing ...

Gadoquatrane showed pediatric safety and pharmacokinetic profiles similar to adults in a study, supporting use as a low-dose ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

As she prepares to change medications for her MS, columnist Leigh Anne Nelson explores the U.S. government’s registry on ...

Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.

A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...